abstract |
The present invention provides an antibody that binds to human interleukin-25 (IL-25) and a method for using the same. According to certain embodiments, the antibodies of the invention bind to human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind to human IL-25 and block IL-25-mediated cell signaling. Antibodies of the invention may be fully human, non-naturally occurring antibodies. Antibodies of the invention are useful in the treatment of various conditions associated with the activity or expression of IL-25, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease including ulcerative colitis and Crohn's disease ( IBD), atopic dermatitis (AD), and eosinophilic granulomatosis with polyangiitis (EGPA) (also known as Churg‑Strauss syndrome). |